Gold rally may be losing steam but no major correction seen: DB
Director Manuel Hidalgo Medina of Guardant Health, Inc. (NASDAQ:GH), a $6.8 billion healthcare company that has seen its stock surge nearly 80% year-to-date despite an 8.8% decline last week, sold 2,165 shares of common stock on September 12, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $54.1574, for a total transaction value of $117,250.
The prices for the shares sold ranged from $54.1501 to $54.1651. Following the transaction, Hidalgo Medina directly owns 851 shares of Guardant Health .
In other recent news, Guardant Health announced significant developments in its operations and strategic partnerships. The company reported improved results for its Shield colon cancer screening test, with a one-point increase in overall sensitivity and a seven-point improvement in stage 1 sensitivity, maintaining the same specificity. This led BTIG to raise its price target for Guardant Health to $70, maintaining a Buy rating. Additionally, Leerink Partners reiterated its Outperform rating and a $70 price target, highlighting the Shield v2 assay’s improved sensitivity for colorectal cancer detection.
In a strategic move, Guardant Health partnered with PathGroup to expand access to Shield, its FDA-approved blood test for colorectal cancer screening. This partnership will extend Shield’s availability to over 250 hospitals and health systems, reaching more than 15,000 PathGroup-affiliated physicians across 25 states. In governance news, Guardant Health appointed Alex M. Azar II, former Secretary of the U.S. Department of Health and Human Services, to its board of directors. Despite these positive developments, Evercore ISI maintained an Outperform rating and a $60 price target, noting that the ECLIPSE study results were consistent with previous findings, with no significant improvements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.